candesartan has been researched along with Cardiac Remodeling, Ventricular in 39 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results suggest that candesartan treatment following myocardial infarction may potentially be useful in terms of improving post-myocardial infarction cardiac remodeling." | 9.69 | Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients. ( Altunkeser, BB; Ates, MS; Aydoğan, C; Aygül, N; Demir, K; Polat, OC; Tezcan, H; Toprak, AM; Tunçez, A; Yalcin, MU, 2023) |
| "The patients with essential hypertension were randomly divided into 2 groups; 1 group was treated with an ARB, candesartan (8 mg/day), for 1 year (ARB group) and other group was treated with the ARB for the first 6 months and with the ARB plus SPRL (25 mg/day) for the next 6 months (combination group)." | 9.12 | Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin II type 1 receptor antagonist on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 8.82 | Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. ( Omura, T; Yoshikawa, J; Yoshiyama, M, 2004) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 7.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "Our results suggest that candesartan treatment following myocardial infarction may potentially be useful in terms of improving post-myocardial infarction cardiac remodeling." | 5.69 | Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients. ( Altunkeser, BB; Ates, MS; Aydoğan, C; Aygül, N; Demir, K; Polat, OC; Tezcan, H; Toprak, AM; Tunçez, A; Yalcin, MU, 2023) |
| " Chronic administration of a subdepressor dose of an angiotensin II type 1 receptor blocker candesartan reduced the pressure overload-induced dihydroethidium and 4-HNE signals at day 3." | 5.33 | Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. ( Fukui, D; Imaizumi, T; Kai, H; Kudo, H; Kuwahara, F; Mori, T; Sugi, Y; Tahara, N; Takayama, N; Takemiya, K; Tokuda, K; Yasukawa, H, 2006) |
| " A total of 154 untreated hypertensive patients, aged 40 to 66 years, with World Health Organization stage I or II hypertension and left ventricular hypertrophy, were randomized to receive placebo, candesartan (32 mg), each of these plus aspirin (300 mg/d), or the same preparations in a reverse order, for 3 weeks, with a 3-week washout period between treatments." | 5.14 | Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial. ( Chiariello, M; De Rosa, ML, 2009) |
| "The patients with essential hypertension were randomly divided into 2 groups; 1 group was treated with an ARB, candesartan (8 mg/day), for 1 year (ARB group) and other group was treated with the ARB for the first 6 months and with the ARB plus SPRL (25 mg/day) for the next 6 months (combination group)." | 5.12 | Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006) |
| "The objective of this study was to determine if adding spironolactone to an angiotensin II receptor blocker improves left ventricular (LV) function, mass, and volumes in chronic heart failure." | 5.12 | Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. ( Chan, AK; Chan, WW; Lam, W; Lam, YY; Sanderson, JE; So, N; Wang, M; Wang, T; Wong, JT; Wu, EB; Yeung, L; Yip, G; Yu, CM; Zhang, Y, 2007) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin II type 1 receptor antagonist on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 4.82 | Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. ( Omura, T; Yoshikawa, J; Yoshiyama, M, 2004) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 3.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "Animals were randomized to rapid right ventricular-pacing (250 beats/min for 3 weeks) to severe heart failure and treated with candesartan (10 mg/kg daily, n = 8) or placebo (n = 8) from day 3 onwards, or no pacing (sham, n = 7)." | 3.74 | Selective type 1 angiotensin II receptor blockade attenuates oxidative stress and regulates angiotensin II receptors in the canine failing heart. ( Jugdutt, BI; Konig, A; Liu, P; Moe, G, 2008) |
| "To determine whether therapy with the angiotensin II type 1 receptor blocker (ARB) candesartan and the comparator angiotensin-converting-enzyme inhibitor (ACEI) enalapril during healing after reperfused ST-elevation myocardial infarction (RSTEMI) limit adverse remodeling of infarct zone (IZ) collagens and left ventricular (LV) diastolic dysfunction, we randomized 24 dogs surviving anterior RSTEMI (90-min coronary occlusion) to placebo, candesartan, and enalapril therapy between day 2 and 42." | 3.74 | Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction. ( Idikio, H; Jugdutt, BI; Uwiera, RR, 2007) |
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| "Reverse ventricular remodeling obtained with carvedilol, ramipril/candesartan, and spironolacton is associated with decreases in left ventricular end-diastolic volume, left ventricular end-systolic volume, tenascin-C levels, and NT-proBNP levels." | 2.78 | Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy. ( Akpek, M; Kaya, EG; Kaya, MG; Lam, YY; Sarli, B; Topsakal, R, 2013) |
| "Treatment with Candesartan (2mg/kg per day) could effectively downregulate Smad3 and fibronectin accompanied by upregulating of Smad7." | 1.38 | Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. ( Li, H; Liu, X; Wang, S; Yu, H; Zhao, G, 2012) |
| "With candesartan pretreatment, LV fractional shortening and ejection fraction increased (P<0." | 1.33 | Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction. ( Castellano, L; Do, R; Gaballa, MA; Goldman, S; Juneman, E; Phan, H; Thai, H, 2006) |
| " Chronic administration of a subdepressor dose of an angiotensin II type 1 receptor blocker candesartan reduced the pressure overload-induced dihydroethidium and 4-HNE signals at day 3." | 1.33 | Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. ( Fukui, D; Imaizumi, T; Kai, H; Kudo, H; Kuwahara, F; Mori, T; Sugi, Y; Tahara, N; Takayama, N; Takemiya, K; Tokuda, K; Yasukawa, H, 2006) |
| "Candesartan was administered orally (10 mg/kg/day) for one week before rapid pacing and was continued for five weeks." | 1.32 | Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. ( Arakawa, K; Gondo, N; Kumagai, K; Nakashima, H; Saku, K; Urata, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 27 (69.23) | 29.6817 |
| 2010's | 10 (25.64) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Tezcan, H | 1 |
| Tunçez, A | 1 |
| Demir, K | 1 |
| Altunkeser, BB | 1 |
| Aygül, N | 1 |
| Yalcin, MU | 1 |
| Ates, MS | 1 |
| Aydoğan, C | 1 |
| Polat, OC | 1 |
| Toprak, AM | 1 |
| Sarli, B | 1 |
| Topsakal, R | 1 |
| Kaya, EG | 1 |
| Akpek, M | 1 |
| Lam, YY | 2 |
| Kaya, MG | 1 |
| Helske-Suihko, S | 1 |
| Laine, M | 1 |
| Lommi, J | 1 |
| Kaartinen, M | 1 |
| Werkkala, K | 1 |
| Kovanen, PT | 1 |
| Kupari, M | 1 |
| Moe, G | 1 |
| Konig, A | 1 |
| Liu, P | 1 |
| Jugdutt, BI | 4 |
| Kohno, T | 1 |
| Anzai, T | 1 |
| Naito, K | 1 |
| Sugano, Y | 1 |
| Maekawa, Y | 1 |
| Takahashi, T | 1 |
| Yoshikawa, T | 1 |
| Ogawa, S | 1 |
| Palaniyappan, A | 2 |
| Uwiera, RR | 3 |
| Idikio, H | 3 |
| Shigenaga, A | 1 |
| Tamura, K | 2 |
| Dejima, T | 1 |
| Ozawa, M | 1 |
| Wakui, H | 1 |
| Masuda, S | 1 |
| Azuma, K | 1 |
| Tsurumi-Ikeya, Y | 1 |
| Mitsuhashi, H | 1 |
| Okano, Y | 1 |
| Kokuho, T | 1 |
| Sugano, T | 1 |
| Ishigami, T | 1 |
| Toya, Y | 1 |
| Uchino, K | 1 |
| Tokita, Y | 1 |
| Umemura, S | 2 |
| De Rosa, ML | 1 |
| Chiariello, M | 1 |
| Kudo, H | 2 |
| Kai, H | 3 |
| Kajimoto, H | 1 |
| Koga, M | 1 |
| Takayama, N | 2 |
| Mori, T | 2 |
| Ikeda, A | 1 |
| Yasuoka, S | 1 |
| Anegawa, T | 1 |
| Mifune, H | 1 |
| Kato, S | 1 |
| Hirooka, Y | 1 |
| Imaizumi, T | 3 |
| Asmer, I | 1 |
| Adawi, S | 1 |
| Flugelman, MY | 1 |
| Shiran, A | 1 |
| Dahl, JS | 2 |
| Videbaek, L | 1 |
| Poulsen, MK | 2 |
| Pellikka, PA | 2 |
| Veien, K | 1 |
| Andersen, LI | 1 |
| Haghfelt, T | 1 |
| Møller, JE | 2 |
| Jehle, AB | 1 |
| Xu, Y | 2 |
| Dimaria, JM | 1 |
| French, BA | 1 |
| Epstein, FH | 1 |
| Berr, SS | 1 |
| Roy, RJ | 1 |
| Kemp, BA | 1 |
| Carey, RM | 1 |
| Kramer, CM | 1 |
| Karnik, SS | 1 |
| Unal, H | 1 |
| Yasuda, N | 1 |
| Akazawa, H | 1 |
| Ito, K | 1 |
| Shimizu, I | 1 |
| Kudo-Sakamoto, Y | 1 |
| Yabumoto, C | 1 |
| Yano, M | 1 |
| Yamamoto, R | 1 |
| Ozasa, Y | 1 |
| Minamino, T | 1 |
| Naito, AT | 1 |
| Oka, T | 1 |
| Shiojima, I | 1 |
| Paradis, P | 1 |
| Nemer, M | 1 |
| Komuro, I | 2 |
| Yu, H | 1 |
| Zhao, G | 1 |
| Li, H | 1 |
| Liu, X | 1 |
| Wang, S | 1 |
| Videbæk, L | 1 |
| Rudbæk, TR | 1 |
| Menon, V | 1 |
| Jugdutt, C | 1 |
| Shimizu, T | 1 |
| Hirayama, H | 1 |
| Hiramitsu, S | 1 |
| Shimizu, K | 1 |
| Yoshida, O | 1 |
| Klein, HU | 1 |
| Goette, A | 1 |
| Kumagai, K | 1 |
| Nakashima, H | 1 |
| Urata, H | 1 |
| Gondo, N | 1 |
| Arakawa, K | 1 |
| Saku, K | 1 |
| Umemoto, S | 1 |
| Kawahara, S | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| McKelvie, RS | 2 |
| Rouleau, JL | 2 |
| White, M | 2 |
| Afzal, R | 2 |
| Young, JB | 1 |
| Maggioni, AP | 2 |
| Held, P | 1 |
| Yusuf, S | 2 |
| Tokuda, K | 2 |
| Kuwahara, F | 2 |
| Yoshiyama, M | 1 |
| Omura, T | 1 |
| Yoshikawa, J | 1 |
| Yan, RT | 1 |
| Yan, AT | 1 |
| Hall, C | 1 |
| Latini, R | 1 |
| Floras, J | 1 |
| Masson, S | 1 |
| Taniguchi, I | 1 |
| Kawai, M | 1 |
| Date, T | 1 |
| Yoshida, S | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Shimizu, M | 1 |
| Mochizuki, S | 1 |
| Ariff, B | 1 |
| Zambanini, A | 1 |
| Vamadeva, S | 1 |
| Barratt, D | 1 |
| Sever, P | 1 |
| Stanton, A | 1 |
| Hughes, A | 1 |
| Thom, S | 1 |
| Thai, H | 1 |
| Castellano, L | 1 |
| Juneman, E | 1 |
| Phan, H | 1 |
| Do, R | 1 |
| Gaballa, MA | 1 |
| Goldman, S | 1 |
| Tahara, N | 1 |
| Takemiya, K | 1 |
| Sugi, Y | 1 |
| Fukui, D | 1 |
| Yasukawa, H | 1 |
| Kinugawa, S | 2 |
| Tsutsui, H | 1 |
| Matsushima, S | 1 |
| Ide, T | 1 |
| Inoue, N | 1 |
| Ohta, Y | 1 |
| Yokota, T | 1 |
| Hamaguchi, S | 1 |
| Sunagawa, K | 1 |
| Chan, AK | 1 |
| Sanderson, JE | 1 |
| Wang, T | 1 |
| Lam, W | 1 |
| Yip, G | 1 |
| Wang, M | 1 |
| Zhang, Y | 1 |
| Yeung, L | 1 |
| Wu, EB | 1 |
| Chan, WW | 1 |
| Wong, JT | 1 |
| So, N | 1 |
| Yu, CM | 1 |
| Chrysostomakis, SI | 1 |
| Karalis, IK | 1 |
| Simantirakis, EN | 1 |
| Koutsopoulos, AV | 1 |
| Mavrakis, HE | 1 |
| Chlouverakis, GI | 1 |
| Vardas, PE | 1 |
| Kasama, S | 1 |
| Toyama, T | 1 |
| Sumino, H | 1 |
| Matsumoto, N | 1 |
| Sato, Y | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Ichikawa, S | 1 |
| Suzuki, T | 1 |
| Kurabayashi, M | 1 |
| Nakamura, T | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Yamazaki, T | 1 |
| Yazaki, Y | 1 |
| McMurray, J | 1 |
| Kobayashi, N | 1 |
| Nakano, S | 1 |
| Mita, S | 1 |
| Kobayashi, T | 1 |
| Honda, T | 1 |
| Tsubokou, Y | 1 |
| Matsuoka, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves[NCT00699452] | Phase 3 | 120 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| Beneficio Del Bloqueo Del Sistema Renina-angiotensina Sobre la evolución clínica y el Remodelado Ventricular Tras la colocación de Una prótesis percutánea aórtica (RASTAVI)[NCT03201185] | Phase 4 | 194 participants (Actual) | Interventional | 2018-02-10 | Active, not recruiting | ||
| Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis - Effect of Blockade of the Angiotensin-II Receptor[NCT00294775] | Phase 3 | 140 participants (Anticipated) | Interventional | 2006-02-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for candesartan and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Fai | 2003 |
Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Eplerenone; Mineraloc | 2004 |
[Diabetic heart disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1999 |
13 trials available for candesartan and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients.
Topics: Echocardiography; Humans; Myocardial Infarction; Prospective Studies; Ventricular Remodeling | 2023 |
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Carbazoles; Cardiomyopathy, Dilat | 2013 |
Is blockade of the Renin-Angiotensin system able to reverse the structural and functional remodeling of the left ventricle in severe aortic stenosis?
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazo | 2015 |
Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphen | 2009 |
Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aspirin; Benzimidazol | 2009 |
Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazo | 2010 |
Global strain in severe aortic valve stenosis: relation to clinical outcome after aortic valve replacement.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aortic Valve; Aortic Valve Stenosi | 2012 |
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2005 |
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl | 2006 |
Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Benzimi | 2006 |
Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Blind Meth | 2007 |
Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compo | 2007 |
22 other studies available for candesartan and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Selective type 1 angiotensin II receptor blockade attenuates oxidative stress and regulates angiotensin II receptors in the canine failing heart.
Topics: Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Bipheny | 2008 |
Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; | 2008 |
Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular | 2009 |
Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2009 |
Spontaneous resolution of severe mitral regurgitation in a patient with a flail mitral valve.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Echocardiography; Echocardiograp | 2010 |
A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Coronary Occlu | 2012 |
Angiotensin II receptor-induced cardiac remodeling in mice without angiotensin II.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Gene Expression Regulation; Male; Myocardium; Receptor, | 2012 |
Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2012 |
Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Culture | 2012 |
Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin II and left ventricular remodeling by candesartan and omapatrilat during healing after reperfused myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Bipheny | 2013 |
[Drug therapies following heart failure and myocardial infarction(discussion)].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2002 |
Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation?
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Fibrillation; Benzimidazo | 2003 |
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Fibrillation; Benzimidazo | 2003 |
Sub-depressor dose of angiotensin type-1 receptor blocker inhibits transforming growth factor-beta-mediated perivascular fibrosis in hypertensive rat hearts.
Topics: Administration, Oral; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzi | 2003 |
Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Male; Myocardi | 2006 |
Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2006 |
Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2007 |
Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Blo | 2007 |
Angiotensin II type 1 receptor inhibition is associated with reduced tachyarrhythmia-induced ventricular interstitial fibrosis in a goat atrial fibrillation model.
Topics: Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Compounds; Cardiac Pacing, Artificial; Diseas | 2007 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |
AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Bi | 2000 |
Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats.
Topics: Amides; Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; Hemodynamics; Hype | 2002 |